hexenoyl group comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-09. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
The tumultuous reception that Sfeir received not only signified a historic reconciliation between Maronites and Druze, who fought a war in 1983–1984, but underscored the fact that the banner of Lebanese sovereignty had broad multi-confessional appeal and was a cornerstone for the Cedar Revolution in 2005. For historical and political reasons, social and economic conditions vary among Lebanon's sects. Christians in Beirut dominated the most lucrative financial and commercial sectors, while Muslims had a significant presence in lower value-added industrial sectors. Muslims generally comprised the majority of the working class, while Christians predominated in the middle and upper classes (about 75%), also owning most small and medium-sized enterprises. Researcher Gordon observed that in 1980, the financial income of Christians was approximately 16% higher than that of the Druze and about 58% higher than that of the Shiites.
Tamura proposed in 2011 that the original PTC was formed by the concatenation of tRNAs. Farias et al. (2014) performed ancestral sequence reconstruction on 22 types of tRNA and found a surprisingly high (for billions of years of divergence) 50.4% identity against the modern PTC of Thermus thermophilus, which is also identical in a few other thermophiles. The dinucleotide frequency was also similar across a wider range of bacteria. Prosdocimi et al. (2020) compared a very large collection of PTCs to form an ancestral consensus. From 5'-to-3', the proto-bacterial-PTC is probably formed by the concatenation of tRNAPro, tRNATyr, tRNAPhe, tRNAGln, and tRNAGly. They also cite a few other earlier works on this topic not mentioned here. An alternative view is based on the PTC's pseudotwofold symmetry. A prototype might have just had one half of this system. A 2022 study synthesized and tested a few "half-PTC" two-helix sequences. Some of them dimerize and form peptide bonds when tRNA is given.
Northern: The northern section runs from the Canadian province of Newfoundland and Labrador to the Hudson River. It includes the Long Range Mountains and Annieopsquotch Mountains on the island of Newfoundland, the French Territorial Collectivity of Saint-Pierre and Miquelon southwest of Newfoundland, Chic-Choc Mountains and Notre Dame Range in Quebec and New Brunswick, scattered elevations and small ranges elsewhere in Nova Scotia and New Brunswick, the Longfellow Mountains in Maine, the White Mountains in New Hampshire, the Green Mountains in Vermont, and The Berkshires in Massachusetts, and Connecticut, the Metacomet Ridge Mountains in Connecticut and south-central Massachusetts, and the Adirondack Mountains in New York are all part of the Appalachian Mountains as defined by the governments of Canada and the United States.Mountains of the Long Range in Newfoundland, such as the Cabox and Gros Morne, reach heights of nearly 2,700 ft (800 m). In the Chic-Choc and Notre Dame Mountain ranges in Quebec, the higher summits rise above 4,000 ft (1,200 m) in elevation. Isolated peaks and small ranges in Nova Scotia and New Brunswick vary from 1,000 to 2,700 ft (300 to 800 m). In Maine, several peaks exceed 4,000 ft (1,200 m), including Mount Katahdin at 5,267 feet (1,605 m).
Sources: en.wikipedia.org
=== Colloidal synthesis === Colloidal semiconductor nanocrystals are synthesized from solutions, much like traditional chemical processes. The main difference is the product neither precipitates as a bulk solid nor remains dissolved. Heating the solution at high temperature, the precursors decompose forming monomers which then nucleate and generate nanocrystals. Temperature is a critical factor in determining optimal conditions for the nanocrystal growth. It must be high enough to allow for rearrangement and annealing of atoms during the synthesis process while being low enough to promote crystal growth. The concentration of monomers is another critical factor that has to be stringently controlled during nanocrystal growth. The growth process of nanocrystals can occur in two different regimes: "focusing" and "defocusing". At high monomer concentrations, the critical size (the size where nanocrystals neither grow nor shrink) is relatively small, resulting in growth of nearly all particles. In this regime, smaller particles grow faster than large ones (since larger crystals need more atoms to grow than small crystals) resulting in the size distribution focusing, yielding an improbable distribution of nearly monodispersed particles. The size focusing is optimal when the monomer concentration is kept such that the average nanocrystal size present is always slightly larger than the critical size. Over time, the monomer concentration diminishes, the critical size becomes larger than the average size present, and the distribution defocuses.
== External links == "Calcitonin receptors: CALCRL". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. calcitonin+receptor-like+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) CALCRL human gene location in the UCSC Genome Browser. CALCRL human gene details in the UCSC Genome Browser.
In August and September, the Columbia team enlarged upon the cross section measurements by making a series of exponential "piles". The first piles consisted of a uranium-graphite lattice, consisting of 288 cans, each containing 60 pounds of uranium oxide, surrounded by graphite bricks. Fermi's goal was to determine critical mass necessary to sustain neutron generation. Fermi defined the reproduction factor k for assessing the chain reaction, with a value of 1.0 denoting a sustained chain reaction. In September 1941, Fermi's team was only able to achieve a k value of 0.87. In April 1942, before the project was centralized in Chicago, they had achieved 0.918 by removing moisture from the oxide. In May 1942, Fermi planned a full-scale chain reacting pile, Chicago Pile-1, after one of the exponential piles at Stagg Field reached a k of 0.995. Between 15 September and 15 November, Herbert L. Anderson and Walter Zinn built sixteen exponential piles. Acquisition of purer forms of graphite, without traces of boron and its large cross section, became paramount. Also important was the acquisition of highly purified forms of oxide from Mallinckrodt Chemical Works. Finally, acquiring pure uranium metal from the Ames process, meant the replacement of oxide pseudospheres with Frank Spedding's "eggs". Starting on 16 November 1942, Fermi had Anderson and Zinn working in two twelve-hours shifts, constructing a pile that eventually reached 57 layers by 1 Dec.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.